Heartened by the current studies on the biological aggressiveness of RFWD2 in various cancers, we herein continued with the previous findings in the impact of RFWD2 on MM progression and drug resistance, further proved that targeting RFWD2 could work as a potential treatment approach for MM. The gene discussed is COP1; the disease is Miyoshi myopathy.